Phase i trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 169-173

  Anwer, Khursheed ^a   Kelly, F Joseph ^c   Chu, Christina ^d   Fewell, Jason G ^a   Lewis, Danny ^a   Alvarez, Ronald D ^b  

^a EGEN Inc   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Clearview Cancer Institute   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemotherapy; Gene therapy; Interleukin 12; Ovarian cancer; Plasmid DNA

Indexed keywords

CARBOPLATIN; DOCETAXEL; RECOMBINANT INTERLEUKIN 12;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CELLULITIS; CHILL; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HYPERHIDROSIS; HYPOTENSION; INJECTION SITE ERYTHEMA; INSOMNIA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

EID: 84885321751     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.081     Document Type: Article

References (24)

1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10: 1038-46.
2. Bhoola S, Alvarez R. Novel therapies for recurrent ovarian cancer management. Expert Rev Anticancer Ther 2004;4: 437-48.
3. Whitworth JM, Alvarez RD. Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature. Expert Opin Biol Ther 2011;11: 751-62.
4. Wolf AM. RumpoldH, Reimer D, et al.High IL-12 p35 and IL-23 p19mRNA expression is associated with superior outcome in ovarian cancer. Gynecol Oncol 2010;118: 244-50.
5. Simpson-Abelson MR, Purohit VS, Pang WM, et al. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol 2009;132: 71-82.
6. DeCesare SL, Michelini-Norris B, Blanchard DK, et al. Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system. Gynecol Oncol 1995;57: 86-95.
7. Tran R, Nielsen JS, Wick DA, et al. Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS One 2010;5: 15625-31.
8. Lenzi R, Rosenblum M, Verschraegen C, et al. Phase I study of intraperitoneal recombinant human interleukin-12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 2002;8: 3686-95.
9. Lenzi R, Edward R, June C, et al. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease b 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 2007;5: 66-72.
10. Atkins MB, Robertson MJ, Gordon M, et al. Phase I trial evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3(3): 409-17.
11. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN- induction is associated with clinical response. Clin Cancer Res 2000;6: 1678-92.
12. Cebon J, Jager E, Shackleton MJ, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in patients with advanced malignant melanoma. Cancer Immu 2003;16: 3-7.
13. Rook AH,Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94(3): 902-8.
14. van Herpen CM, Looman M, Zonneveld M, et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the loco regional lymph nodes. Clin Cancer Res 2004;10: 2626-35.
15. Fewell J, Matar M, Slobodkin G, et al. Synthesis and application of biocompatible non-viral gene delivery system for immunogene therapy of cancer. J Control Release 2005;109: 288-98.
16. Fewell JG, Matar MM, Rice JS, et al. Treatment of disseminated ovarian cancer using non-viral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med 2009;11: 718-28.
17. Anwer K, Barnes MN, Fewell JG, et al. Phase-I clinical trial of IL-12 plasmid/polymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 2010;17: 360-9.
18. Malvivini M, Alaniz L, Bayo J, et al. Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to ametronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology 2012;1: 1038-47.
19. Gonzalez-Aparicio M, Alzuguren P, Mauleon I, et al. Oxaliplatin in combination with liver-specific expression of interleukin-12 reduces the immunosuppressive microenvironment of tumors and eradicates metastatic colorectal cancer in mice. Gut 2011;60: 341-9.
20. Torrero M, Li S. Treatment of SCCVII tumors with systemic chemotherapy and interleukin-12 gene therapy combination. Methods Mol Biol 2008: 339-49.
21. Sonabend AM, Velicu S, Ulasov IV, et al. A safety and efficacy study of local delivery of IL-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drug 2008;19: 133-42.
22. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs 2007;11: 37-42.
23. Ozols R. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 2003;21: 2451-3.
24. Hong Y, MagerDE, Blum RA, Jusko WJ. Population pharmacokinetic/ pharmacodynamics modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamics variability. Pharm Res 2007;24(6): 1088-97.